Zimbabwe has declined a substantial American healthcare agreement valued at $367m (£272m) over five years over the United States' request for confidential data.
This move was revealed following a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative has since stated that the US was requesting biological samples for research and commercial purposes while refused to share the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further dialogue to reach a agreement acceptable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
This development follows a comparable situation in Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of citizens' medical information.
After returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on reports, 16 nations in Africa have so far signed similar agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the end products would be available to our people if a future pandemic emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures already established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to ensure that when a country provides its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We welcome further discussions with our US partners on how subsequent co-operation could be structured in a way that respects the independence and interests of both nations."
Medical Community Response
A leading public health body stated it recognised the official position, but suggested that talks should continue since much of the country's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it said.
The halted deal highlights the complex debate between receiving vital international aid and safeguarding local interests in an ever more data-driven world.